ArticleJournal of oncology2022

Clinical Study on the Efficacy of Bevacizumab in Combination with Pembrolizumab on Cellular Immune Function in the Treatment of Driver Gene-Negative Stage IV Lung Adenocarcinoma.

Jun Gong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.